Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-20
    E.g., 2018-10-20

Archive Search

2 results
12:00 AM, Nov 14, 2013  |  BC Innovations | Distillery Therapeutics

Indication: Neurology

V1a receptor antagonist, SRX251, is in Phase I to treat dysmenorrhea. Roche's V1a receptor antagonist, RG7314
12:00 AM, Apr 19, 2012  |  BC Innovations | Strategy

Building tools against autism

in autistic patients. Roche also has another autism compound, the vasopressin 1a (V1a) receptor antagonist RG7314